Prognostic factors in resected non-small cell lung cancer: An immunohistochemical study of 39 cases

Lung Cancer

Volumn 16, Issue 1, 1996, Pages 35-45

  Kwa, H B ^a,c   Verheijen, M G M M ^a   Litvinov, S V ^a   Dijkman, J H ^a   Mooi, W J ^b   Van Krieken, J H J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

immunohistochemistry; non small cell lung carcinoma; prognosis; surgery

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NERVE CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031058439     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(96)00610-1     Document Type: Article

References (33)

1. [1] World Health Organization. In: The World Health Organization Histological Typing of Lung Tumours, 2nd ed. Geneva: World Health Organization, 1981.
2. [2] Hermanek P. Sobin LH. Lung and pleural tumours. In: UICC: TNM classification of malignant tumors. 4th ed. 2nd revision. Geneva: Springer Verlag, 1987; 75-80.
3. [3] Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993; 20: 105-127.
4. [4] Rosenthal SA, Curran WJ. The significance of histology in non-small cell lung cancer. Cancer Treat Rev 1990; 17: 409-425.
5. [5] Ebina M, Steinberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54: 2496-2503.
6. [6] Passlick B, Izbicki JR, Haussinger K, Thetter O, Pantel K. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 1205-1211.
7. [7] Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histology, and oncoprotein expression. Cancer Res 1995; 55: 51-56.
8. [8] Top B, Mooi WJ, Klaver SG, Boerrigter L, Wisman P, Elbers JRJ, Visser S, Rodenhuis S. P53 gene mutation and protein accumulation in human non small cell lung cancer. Int J Cancer (Pred Oncol) 1995; 64: 83-91.
9. [9] Volm M, Efferth T, Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 1992; 12: 11-20.
10. [10] Gazzeri S, Brambilla E, Caron de Fromentel C, Gouyer V, Moro D, Perron P, Berger F, Brambilla C. P53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994; 58: 24-32.
11. [11] Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994; 86: 695-699.
12. [12] Gouyer V, Gazzeri S, Brambilla E, Bolon I, Moro D, Perron P, Benabid AL, Brambilla C. Loss of heterozygosity at the Rb locus correlates with loss of Rb protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer 1994; 58: 818-824.
13. [13] Reissmann PT, Koga H, Takahashi R, Figlin RA, Carmack Holmes E, Piantadosi S, Cordon-Cardo C, Slamon DJ. Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. Oncogene 1993; 8: 1913-1919.
14. [14] Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 1994; 3: 109-113.
15. [15] Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F, Bevilacqua G. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995; 31: 178-183.
16. [16] Garcia de Palazzo IE, Adams GP, Sundaresan P, Wong AJ, Testa JR, Bigner DD, Weiner LM. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53: 3217-3220.
17. [17] Veale D, Kerr N, Gibson GJ, Kelley RJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68: 162-165.
18. [18] Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A. P53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994; 106: 377S-381S.
19. [19] Ozeki Y, Takishima K, Mamiya G. Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumor progression in Clara cell type. Jpn J Cancer Res 1994; 85: 840-846.
20. [20] Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S, Tateishi R. Kimura N. Immunohistochemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: lack of prognostic value. Br J Cancer 1992; 66: 533-536.
21. [21] Pujol JL, Simony J, Demoly P, Charpentier R, Laurent JC, Daures JP, Lehmann M, Guyot V, Godard P. Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis 1993; 148: 1071-1075.
22. [22] Kibbelaar RE, Moolenaar KE, Michalides RJ, van Bodegom PC, Vanderschueren RG. Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991; 27: 431-435.
23. [23] Kwa HB, Michalides RJAM, Dijkman JH, Mooi WJ. The prognostic value of NCAM, P53 and Cyclin D1 in resected non-small cell lung cancer. Lung Cancer 1996; 14: 207-217.
24. r 43 000 membrane glycoprotein associated with human breast cancer. Cancer Res 1986; 46: 1306-1311.
25. [25] Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994; 125: 437-446.
26. [26] Carneiro F, David L, Seruca R, Castedo S, Nesland JM, Sobrinho-Simoes M. Hyperplastic polyposis and diffuse carcinoma of the stomach. A study of a family. Cancer 1993; 72: 323-329.
27. [27] Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
28. [28] Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 1003-1007.
29. [29] Jensen SM, Gazdar AF, Cuttitta F, Russell EK, Linnoila RI. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Cancer Res 1990; 50: 6068-6074.
30. [30] Deftos LJ, Linnoila RI, Carney DN, Burton DW, Leong SS, O'Connor DT, Murray SS, Gazdar AF. Demonstration of Chromogranin A in human neuroendocrine cell lines by immunohistology and immunoassay. Cancer 1988; 62: 92-97.
31. [31] Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic significance of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991; 2: 355-360.
32. [32] Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer 1991; 64: 333-338.
33. [33] Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 1994; 106: 367S-371S.